Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
Viruses · 2023
DOI: 10.3390/v15061350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Ruolan Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, HIV Seropositivity, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG/3TC and 318 (85%) on TBR had both proviral genotype data and ≥1 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society–USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V/I (1%), K65N/R (99% of participants on DTG/3TC and 99% on TBR were virologically suppressed (last on-treatment VL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
- GSK, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK.
- ViiV Healthcare, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK.
- Infektiologikum, Stresemannallee 3, 60596 Frankfurt am Main, Germany.
- Hospital Universitari de Bellvitge, Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
- Northside Clinic, 370 St Georges Rd, Fitzroy North, VIC 3068, Australia.
ORCID-Profile: Chris M Parry, Mark Underwood
Förderung
- ViiV Healthcare
Zitieren
APA
Wang, R., Wright, J., Saggu, P., Ait-Khaled, M., Moodley, R., Parry, C. M., Lutz, T., Podzamczer, D., Moore, R., Górgolas Hernández-Mora, M., Kinder, C., Wynne, B., van Wyk, J., & Underwood, M. (2023). Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144. Viruses. https://doi.org/10.3390/v15061350
Vancouver
Wang R, Wright J, Saggu P, Ait-Khaled M, Moodley R, Parry CM, et al. Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144. Viruses. 2023. doi:10.3390/v15061350
BibTeX
@article{Wang2023,
author = {Wang, Ruolan and Wright, Jonathan and Saggu, Parminder and Ait-Khaled, Mounir and Moodley, Riya and Parry, Chris M and Lutz, Thomas and Podzamczer, Daniel and Moore, Richard and Górgolas Hernández-Mora, Miguel and Kinder, Clifford and Wynne, Brian and van Wyk, Jean and Underwood, Mark},
title = {Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15061350}
}
EUVIMED